Abstract:
Objective and Design: To investigate the suppressive effects of the β-agonist clenbuterol on the release of TNF-α and IL-6 in a lipopolysaccharide (LPS)-model of inflammation, both in vitro and in vivo.¶Material and Subjects: Human U-937 cell line (monocyte-derived macrophages), and male Wistar rats (200-250g).¶Treatment: U-937 macrophages were incubated with LPS at 1 μg/ml, with or without 1.0mM-0.1nM test drugs (clenbuterol and other cAMP elevating agents) for 1-24h. Rats were administered either 1 or 10 μg/kg clenbuterol (or saline) orally, 1h before intraperitoneal administration of 2mg/kg LPS.¶Methods and Results: TNF-α and IL-6 time-concentration profiles were determined both in culture media and plasma, using ELISA' s and bioassays. LPS-mediated release of both cytokines was significantly suppressed by clenbuterol.¶Conclusions: The β-agonist clenbuterol very potently suppresses the LPS-induced release of the pro-inflammatory cytokines TNF-α and IL-6 both in vitro and in vivo.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received 16 March 1999; returned for revision 6 April 1999; accepted by K. Brune 20 June 1999
Rights and permissions
About this article
Cite this article
Izeboud, C., Monshouwer, M., van Miert, A. et al. The β-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPS-induced production of TNF-α and IL-6 in vitro and in vivo. Inflamm. res. 48, 497–502 (1999). https://doi.org/10.1007/s000110050493
Published:
Issue Date:
DOI: https://doi.org/10.1007/s000110050493